Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Phathom Pharmaceuticals stock price, quote, forecast and news

PHAT
US71722W1071
A2PT0F

Price

11.46
Today +/-
+0
Today %
+0 %
P

Phathom Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Phathom Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Phathom Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Phathom Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Phathom Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Phathom Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Phathom Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Phathom Pharmaceuticals’s growth potential.

Phathom Pharmaceuticals Revenue, EBIT and net profit per share

DatePhathom Pharmaceuticals RevenuePhathom Pharmaceuticals EBITPhathom Pharmaceuticals Net Income
2029e816.89 M undefined0 undefined74.04 M undefined
2028e720.16 M undefined216.7 M undefined10.15 M undefined
2027e523.71 M undefined68.26 M undefined-93.75 M undefined
2026e365.99 M undefined-103.48 M undefined-100.91 M undefined
2025e165.15 M undefined-226.37 M undefined-229.49 M undefined
2024e42.04 M undefined-269.5 M undefined-314.56 M undefined
2023682,000 undefined-167.31 M undefined-201.59 M undefined
20220 undefined-172.44 M undefined-197.72 M undefined
20210 undefined-135.08 M undefined-143.88 M undefined
20200 undefined-125.67 M undefined-129.07 M undefined
20190 undefined-106.22 M undefined-255.13 M undefined
20180 undefined-1.23 M undefined-1.29 M undefined

Phathom Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
00000042165365523720816
-------292.86121.2143.2937.6713.33
------------
000000000000
-1-106-125-135-172-167-269-226-103682160
-------640.48-136.97-28.2213.0030.00-
-1-255-129-143-197-201-314-229-100-931074
-25,400.00-49.4110.8537.762.0356.22-27.07-56.33-7.00-110.75640.00
25.8824.7333.2330.5139.1251.29000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Phathom Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Phathom Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Phathom Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Phathom Pharmaceuticals's financial health and stability.

Assets

Phathom Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Phathom Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Phathom Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Phathom Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-1-255-129-143-197-201
000000
000000
0-951-271911
022813395597
0134711
000000
-1-36-69-148-146-137
00-10-1-1
0-25-10-1-1
0-250000
000000
1113254295211
019189124155
130411444120367
------
000000
024243-104-27228
-1.02-36.64-70.73-148.79-147.57-139.21
000000

Phathom Pharmaceuticals stock margins

The Phathom Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Phathom Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Phathom Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Phathom Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Phathom Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Phathom Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Phathom Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Phathom Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Phathom Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Phathom Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Phathom Pharmaceuticals Margin History

Phathom Pharmaceuticals Gross marginPhathom Pharmaceuticals Profit marginPhathom Pharmaceuticals EBIT marginPhathom Pharmaceuticals Profit margin
2029e75.51 %0 %9.06 %
2028e75.51 %30.09 %1.41 %
2027e75.51 %13.03 %-17.9 %
2026e75.51 %-28.27 %-27.57 %
2025e75.51 %-137.07 %-138.96 %
2024e75.51 %-641.12 %-748.3 %
202375.51 %-24,532.55 %-29,558.95 %
202275.51 %0 %0 %
202175.51 %0 %0 %
202075.51 %0 %0 %
201975.51 %0 %0 %
201875.51 %0 %0 %

Phathom Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Phathom Pharmaceuticals earnings per share therefore indicates how much revenue Phathom Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Phathom Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Phathom Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Phathom Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Phathom Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Phathom Pharmaceuticals Revenue, EBIT and net profit per share

DatePhathom Pharmaceuticals Sales per SharePhathom Pharmaceuticals EBIT per sharePhathom Pharmaceuticals Earnings per Share
2029e13.95 undefined0 undefined1.26 undefined
2028e12.3 undefined0 undefined0.17 undefined
2027e8.95 undefined0 undefined-1.6 undefined
2026e6.25 undefined0 undefined-1.72 undefined
2025e2.82 undefined0 undefined-3.92 undefined
2024e0.72 undefined0 undefined-5.37 undefined
20230.01 undefined-3.26 undefined-3.93 undefined
20220 undefined-4.41 undefined-5.05 undefined
20210 undefined-4.43 undefined-4.72 undefined
20200 undefined-3.78 undefined-3.88 undefined
20190 undefined-4.3 undefined-10.32 undefined
20180 undefined-0.05 undefined-0.05 undefined

Phathom Pharmaceuticals business model

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Phathom Pharmaceuticals SWOT Analysis

Strengths

Phathom Pharmaceuticals Inc has several notable strengths:

  • Strong and experienced management team with a successful track record in the pharmaceutical industry.
  • Cutting-edge research and development capabilities, leading to the creation of innovative and potentially disruptive products.
  • Solid financial position, enabling investment in future growth and expansion.
  • Well-established relationships with key stakeholders, including healthcare professionals, regulatory bodies, and strategic partners.
  • Strong intellectual property portfolio, providing a competitive advantage and protection against potential competitors.

Weaknesses

Despite its strengths, Phathom Pharmaceuticals Inc also faces certain weaknesses:

  • Relatively small market presence compared to established pharmaceutical giants, limiting brand recognition and market share.
  • Dependence on limited product pipeline, exposing the company to risks associated with product failures or market rejection.
  • Vulnerability to changes in regulatory policies and prolonged approval processes, potentially delaying product commercialization.
  • Limited resources for expanding marketing efforts and distribution channels, hindering market penetration.
  • Potential difficulty in attracting and retaining top talent, due to competition in the industry.

Opportunities

Phathom Pharmaceuticals Inc can capitalize on the following opportunities:

  • Growing demand for innovative treatment options in gastrointestinal therapies, offering a favorable market environment.
  • Collaboration and partnerships with larger pharmaceutical companies, enabling access to additional resources and market reach.
  • Expansion into international markets with high unmet medical needs, paving the way for increased revenue and global presence.
  • Investment in research and development to explore new therapeutic areas and potential product pipelines.
  • Leveraging advancements in technology and digital platforms to enhance marketing strategies and reach a wider audience.

Threats

Phathom Pharmaceuticals Inc faces the following threats:

  • Intense competition from established pharmaceutical companies, making it challenging to capture significant market share.
  • Stringent regulatory requirements and compliance standards, potentially slowing down product development and market entry.
  • Economic downturns and changes in healthcare policies, leading to pricing pressures and reduced market access.
  • Potential emergence of alternative therapies or treatment options, posing a threat to Phathom Pharmaceuticals' current products.
  • Risk of intellectual property infringements and legal disputes, affecting the company's competitive advantage and profitability.

Phathom Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Phathom Pharmaceuticals shares outstanding

The number of shares was Phathom Pharmaceuticals in 2023 — This indicates how many shares 51.289 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Phathom Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Phathom Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Phathom Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Phathom Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Phathom Pharmaceuticals.

Phathom Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-1.34 -1.42  (-6.34 %)2024 Q1
12/31/2023-1.1 -1.39  (-26.54 %)2023 Q4
9/30/2023-0.91 -0.76  (16.42 %)2023 Q3
6/30/2023-1 -0.84  (15.84 %)2023 Q2
3/31/2023-1.29 -0.89  (30.78 %)2023 Q1
12/31/2022-1.38 -1.33  (3.53 %)2022 Q4
9/30/2022-1.34 -1.32  (1.79 %)2022 Q3
6/30/2022-1.05 -1.33  (-26.59 %)2022 Q2
3/31/2022-0.99 -1.07  (-8.37 %)2022 Q1
12/31/2021-1.05 -0.95  (9.43 %)2021 Q4
1
2

Eulerpool ESG Scorecard© for the Phathom Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

58

👫 Social

86

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Phathom Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
5.97 % Abingworth Management Limited3,496,808012/31/2023
4.94 % Invesco Advisers, Inc.2,892,757-240,80412/31/2023
4.77 % Takeda Pharmaceutical Co Ltd2,790,480-362,7374/9/2024
4.07 % BlackRock Institutional Trust Company, N.A.2,384,358205,22912/31/2023
3.89 % Ensign Peak Advisors, Inc.2,280,000547,82812/31/2023
3.35 % New Enterprise Associates (NEA)1,960,169683,57412/31/2023
3.33 % The Vanguard Group, Inc.1,949,89633,76712/31/2023
2.94 % Avidity Partners Management LP1,721,580104,28012/31/2023
2.49 % Gilder Gagnon Howe & Co. LLC1,455,132145,08412/31/2023
2.19 % 683 Capital Management LLC1,280,000180,00012/31/2023
1
2
3
4
5
...
10

Phathom Pharmaceuticals Executives and Management Board

Ms. Terrie Curran54
Phathom Pharmaceuticals President, Chief Executive Officer, Director (since 2019)
Compensation 5.04 M
Dr. Azmi Nabulsi63
Phathom Pharmaceuticals Co-Founder, Chief Operating Officer
Compensation 2.76 M
Ms. Molly Henderson53
Phathom Pharmaceuticals Chief Financial Officer and Business Officer
Compensation 2.65 M
Mr. Frank Karbe54
Phathom Pharmaceuticals Independent Director
Compensation 252,116
Mr. Michael Cola63
Phathom Pharmaceuticals Independent Chairman of the Board (since 2019)
Compensation 170,149
1
2

Most common questions regarding Phathom Pharmaceuticals

What values and corporate philosophy does Phathom Pharmaceuticals represent?

Phathom Pharmaceuticals Inc represents values and a corporate philosophy focused on advancing the treatment of gastrointestinal diseases. With a commitment to innovation and scientific excellence, Phathom Pharmaceuticals Inc strives to develop novel therapies to improve patients' lives. The company's mission is to address unmet medical needs in areas such as acid-related disorders, leveraging its expertise and research capabilities. By combining cutting-edge science with a patient-centric approach, Phathom Pharmaceuticals Inc aims to provide effective and safe treatment options for individuals living with gastrointestinal conditions.

In which countries and regions is Phathom Pharmaceuticals primarily present?

Phathom Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Phathom Pharmaceuticals achieved?

Phathom Pharmaceuticals Inc has achieved several significant milestones. One notable accomplishment is the FDA approval of their lead product, called Odevixibat, for the treatment of progressive familial intrahepatic cholestasis (PFIC). This milestone showcases the company's dedication to developing novel therapies for rare and serious gastrointestinal diseases. Furthermore, Phathom Pharmaceuticals Inc has successfully completed clinical trials that demonstrated the safety and efficacy of Odevixibat, positioning the company as a potential leader in the field. With these achievements, Phathom Pharmaceuticals Inc continues to make strides towards providing innovative treatment options for patients in need.

What is the history and background of the company Phathom Pharmaceuticals?

Phathom Pharmaceuticals Inc is a renowned pharmaceutical company focused on developing innovative treatments for gastrointestinal diseases. Founded in 2018, the company aims to address unmet medical needs and improve patients' quality of life. With a team of experienced researchers and medical experts, Phathom Pharmaceuticals Inc has made significant strides in the field of acid-related disorders. They have developed a unique pipeline of potential therapies targeting diseases like gastroesophageal reflux disease (GERD) and other related conditions. Combining cutting-edge science with strong clinical expertise, Phathom Pharmaceuticals Inc is committed to delivering effective and safe treatments to patients worldwide.

Who are the main competitors of Phathom Pharmaceuticals in the market?

The main competitors of Phathom Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in gastroenterology and gastrointestinal disorders. Some notable competitors include Takeda Pharmaceutical Company Limited, AstraZeneca plc, and Pfizer Inc. These companies also focus on developing innovative therapies and drugs to address similar medical conditions as Phathom Pharmaceuticals Inc. However, Phathom Pharmaceuticals Inc distinguishes itself through its unique approach and proprietary technology, positioning it as a leading contender in the market.

In which industries is Phathom Pharmaceuticals primarily active?

Phathom Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Phathom Pharmaceuticals?

The business model of Phathom Pharmaceuticals Inc is focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company's primary focus is on developing treatments for acid-related disorders, including gastroesophageal reflux disease (GERD). Phathom Pharmaceuticals Inc aims to address the unmet medical needs of patients suffering from these conditions by developing differentiated and effective therapies. By leveraging their expertise in the field of gastrointestinal diseases, Phathom Pharmaceuticals Inc is dedicated to providing improved treatment options and enhancing the quality of life for patients.

What is the P/E ratio of Phathom Pharmaceuticals 2024?

The Phathom Pharmaceuticals P/E ratio is -1.87.

What is the P/S ratio of Phathom Pharmaceuticals 2024?

The Phathom Pharmaceuticals P/S ratio is 13.98.

What is the AlleAktien quality score of Phathom Pharmaceuticals?

The AlleAktien quality score for Phathom Pharmaceuticals is 4/10.

What is the revenue of Phathom Pharmaceuticals 2024?

The expected Phathom Pharmaceuticals revenue is 42.04 M USD.

How high is the profit of Phathom Pharmaceuticals 2024?

The expected Phathom Pharmaceuticals profit is -314.56 M USD.

What is the business model of Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc. is a biopharmaceutical company based in the United States that focuses on the development and marketing of novel therapeutics for gastrointestinal diseases. The company develops and distributes drugs for upper gastrointestinal tract diseases such as reflux disease, gastric ulcers, and other acid-related conditions. The business model of Phathom Pharmaceuticals is designed to create sustainable value for investors through the establishment of a diversified portfolio of drugs in the gastroenterology field. The company utilizes its expertise in research and development and its partnerships in the pharmaceutical market to achieve this. Phathom Pharmaceuticals has focused on the development of the acid suppressant Rabeprazole (trade name: Zegrid), which is used for the treatment of gastroesophageal reflux and gastric and duodenal ulcers. It is a combination product that falls under both proton pump inhibitors and H2 antagonists. What sets it apart is that it was developed using a proprietary formulation approach to achieve effective control of acid production in the stomach. The company has a strong pipeline of drugs in various stages of clinical development, offering promising therapy options for different gastrointestinal diseases and supporting Phathom Pharmaceuticals' long-term business model. Phathom Pharmaceuticals operates its business through a centralized sales strategy and markets its products through its own sales personnel. The company relies on a collaborative approach with doctors and healthcare organizations to increase acceptance and use of its products. The company also pursues an active strategy to expand its global presence through tariff agreements for the marketing of its products in Europe and other key markets, as well as through international partnerships and joint ventures. Overall, Phathom Pharmaceuticals' business model is aimed at bringing innovative therapies for gastrointestinal diseases to the market and providing a more effective option for preventing gastrointestinal diseases worldwide. With targeted research and development and the establishment of strong partnerships and collaborations, the company offers a solid foundation for long-term growth and success.

What is the Phathom Pharmaceuticals dividend?

Phathom Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Phathom Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Phathom Pharmaceuticals or the company does not pay out a dividend.

What is the Phathom Pharmaceuticals ISIN?

The ISIN of Phathom Pharmaceuticals is US71722W1071.

What is the Phathom Pharmaceuticals WKN?

The WKN of Phathom Pharmaceuticals is A2PT0F.

What is the Phathom Pharmaceuticals ticker?

The ticker of Phathom Pharmaceuticals is PHAT.

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Phathom Pharmaceuticals in the year 2023?

In the year 2023, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.

All fundamentals about Phathom Pharmaceuticals

Our stock analysis for Phathom Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phathom Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.